Posted by Michael Wonder on 08 Jul 2019
ADMA Biologics receives FDA approval for license transfers for Bivigam and Nabi-HB
8 July 2019 - All aspects of the Biotest Therapy Business Unit acquisition are successfully completed.
ADMA Biologics announces the United States FDA has notified ADMA the licenses for Bivigam and Nabi-HB have been revoked from Biotest Pharmaceuticals Corporation and transferred and issued to ADMA.
